Phosphatidylinositol 3-kinase signals activate a selective subset of Rac/Rho-dependent effector pathways  by Rei, Karin et al.
Phosphatidylinositol 3-kinase signals activate a selective 
subset of Rac/Rho-dependent effector pathways
Karin Reif*, Catherine D. Nobes†, George Thomas‡, Alan Hall† and 
Doreen A. Cantrell*
Background: Phosphatidylinositol 3′-hydroxyl kinase (PI 3-kinase) is activated by
many growth factor receptors and is thought to exert its cellular functions
through the elevation of phosphatidylinositol (3,4,5)-triphosphate levels in the
cell. PI 3-kinase is required for growth-factor induced changes of the actin
cytoskeleton which are mediated by the GTPases Rac and Rho. Recently, a role
for Rac and Rho in regulating gene transcription has become evident.
Results: Here, we show that membrane targeting of the p110 catalytic subunit,
but not the p85 regulatory subunit, of PI 3-kinase generates a constitutively
active enzyme that allows us to assess the relative contribution of PI 3-kinase
activation to a particular cellular response. Expression of this active PI 3-kinase
induced actin reorganization in the form of Rac-mediated lamellipodia and focal
complexes, and Rho-mediated stress fibres and focal adhesions. However,
expression of active PI 3-kinase did not induce the Ras/Rac/Rho signalling
pathways that regulate gene transcription controlled by the c-fos promoter, the
c-fos serum response element or the transcription factors Elk-1 and AP-1.
Conclusions: Our results demonstrate that PI 3-kinase induces a selective
subset of cellular responses, but is not sufficient to stimulate the full repertoire of
Rac- or Rho-mediated responses.
Background
Stimulation of cells with a wide variety of agonists results
in the activation of phosphatidylinositol 3′-hydroxyl
kinase (PI 3-kinase) and a rapid elevation of the levels of
phosphatidylinositol (3,4,5)-trisphosphate (PI(3,4,5)P3)
and phosphatidylinositol (3,4)-bisphosphate (PI(3,4)P2).
PI 3-kinase is involved in cellular transformation or sig-
nalling by receptor and non-receptor tyrosine kinases in
many cells. The form of PI 3-kinase implicated in these
processes comprises a regulatory 85 kDa subunit contain-
ing two Src homology 2 (SH2) domains and (at its amino
terminus) one SH3 domain, and a catalytic 110 kDa
subunit [1,2]. In response to extracellular stimuli, PI 3-
kinase has been shown to associate physically with several
signalling proteins, including growth factor receptors such
as the platelet-derived growth factor (PDGF) receptor,
non-receptor tyrosine kinases of the Src family, Abl or Crk
[3], and, more recently, GTP-binding proteins of the Ras
and Rho families [4–6].
Initial studies to identify the cellular functions of PI 3-
kinase used mutant receptors whose phosphotyrosine-
binding sites for PI 3-kinase were replaced with
phenylalanine [7,8], or used a p85 mutant that lacked the
p110-binding site [9,10]. These mutants prevent the
recruitment of PI 3-kinases into activated receptor com-
plexes, but such dominant interfering approaches cannot
distinguish between the requirement for two proteins that
bind to the same site [11]. Additional tools for the study of
PI 3-kinase effector pathways are inhibitors of PI 3-kinase
function, such as wortmannin or the LY294002 compound,
which compete for the lipid- or the ATP-binding sites on
PI 3-kinase, respectively.
A recent advance in PI 3-kinase signalling studies has
come from experiments with activated mutants generated
by targeting the p110 catalytic subunit to the membrane.
Studies comparing the effects of activating and interfering
approaches have concluded that PI 3-kinase signals are
necessary and sufficient for activation of p70s6k [12], a
serine/threonine kinase, specific for ribosomal protein S6,
which is required for cells to enter S phase after mitogen
stimulation [13]. PI 3-kinase has also been shown to be
required for activation of the extracellular signal-regulated
kinase (ERK) pathway in several cell systems [14,15],
although the expression of an activated PI 3-kinase does
not seem to be sufficient for activation of the ERKs in
mammalian cells [12]. These results demonstrate that
PI 3-kinase can either function alone to initiate cellular
responses or act in concert with other signalling pathways.
PI 3-kinase has also been shown, by the use of inhibitors,
to be involved in the regulation of the actin cytoskeleton
by growth factors such as PDGF or insulin [16–18]. Growth
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factors trigger membrane ruffling, and the subsequent for-
mation of actin stress fibres, by a mechanism that is depen-
dent on the function of the Rho family GTPases Rac and
Rho, respectively [19]. The expression of constitutively
active forms of these proteins, V12Rac and V14Rho, can
mimic the responses induced by PDGF: V12Rac induces
membrane ruffling and focal complex formation, and
V14Rho induces actin stress fibres and focal adhesion
assembly [19,20]. The activation of PI 3-kinase is necessary
for PDGF activation of Rac- and Rho-mediated rearrange-
ments of the actin cytoskeleton [16,17]; indeed, previous
studies have suggested that PI 3-kinase may regulate
GTP-loading of Rac [21] and, hence, regulate Rho [17,19].
It is unclear, however, whether PI 3-kinase activation is
sufficient to induce Rac- and Rho-mediated cytoskeletal
rearrangements or whether PI 3-kinase is a single compo-
nent of more complex activation processes.
Comprehensive studies have recently established an addi-
tional role for Rac and Rho in mediating transcriptional
regulation of the c-fos serum response element (SRE) [22].
The data concerning a role of PI 3-kinase in regulating
SRE transcription has been controversial: some studies
state that PI 3-kinase function is required for SRE induc-
tion [10,15], whereas others could not define a role for
PI 3-kinase in this response [22]. Such discrepancies could
be explained by the existence of parallel compensatory
pathways. Information concerning the ability of active
PI 3-kinase to generate positive signals that regulate Rac/
Rho transcription factor responses would thus be of value.
A key question is whether PI 3-kinase is a general stimula-
tor of Rac and Rho function in cells.
We investigated the ability of constitutively active PI 3-
kinase to initiate Rac/Rho-mediated cytoskeletal
rearrangements and Rac/Rho-mediated activation of tran-
scription factor pathways. Our strategy to generate a con-
stitutively active mutant was to localize subunits of
PI 3-kinase to the membrane. Here, we show that mem-
brane-targeting of the p110a catalytic subunit of PI 3-
kinase generates a constitutively active enzyme that can
induce actin reorganization, forming Rac-mediated mem-
brane ruffles and focal complexes and Rho-mediated
stress fibres and focal adhesions. However, expression of
active PI 3-kinase did not induce Ras/Rac/Rho signalling
pathways that can regulate transcription of c-fos, c-fos SRE,
or the transcription factors AP-1 or Elk-1. Hence, PI 3-
kinase induces a selective subset of cellular responses but
is not sufficient to stimulate the full range of Rac- or Rho-
mediated responses.
Results
Construction and biochemical characterization of
membrane-targeted rCD2–PI 3-kinase chimeras
To localize PI 3-kinase at the membrane, we constructed
chimeric molecules in which the cytoplasmic domain of
the rat CD2 (rCD2) cell-surface antigen was replaced with
either subunit of PI 3-kinase (Fig. 1a): the extracellular
and transmembrane domains of the rCD2 antigen were
linked to the amino terminus of p85a (rCD2p85) or p110a
(rCD2p110). As a control, a rCD2p110 construct with an
inactivating point mutation (the arginine at position 1130
replaced with a proline; R1130P) in the ATP-binding site
[23], which abolishes its kinase activity (rCD2p110-R/P),
was generated. These fusion proteins were transiently
expressed in Cos7 cells, and western-blot analysis of the
resulting protein chimeras with rCD2 monoclonal antibod-
ies revealed the presence of molecular species of the pre-
dicted masses (Fig. 1b). Cell-surface expression of the
different rCD2–PI 3-kinase chimeras was confirmed by
flow cytometric immunofluorescence analysis with an
anti-rCD2 monoclonal antibody (Fig. 1c).
To assess whether rCD2–PI 3-kinase chimeras had lipid
kinase activity, the chimeras were immunoprecipitated
with an anti-rCD2 monoclonal antibody and subjected to
PI kinase assays in vitro. rCD2p110 had strong PI 3-kinase
activity in vitro, which was dependent on the integrity of
the p110 ATP-binding site — there was no detectable
lipid kinase activity in comparable immunocomplexes of
rCD2p110-R/P (Fig. 1d). These results show that the
fusion of p110 to the rCD2 extracellular and transmem-
brane domains does not adversely affect the folding of the
protein and thus destroy the catalytic activity of the
enzyme. There was also low-level PI  kinase activity asso-
ciated with the rCD2p85 chimera. Western-blot analysis
confirmed that this reflected an association of rCD2p85
with the endogenous p110a catalytic subunit of PI 3-
kinase (data not shown).
To explore the effect of membrane recruitment of the PI 3-
kinase subunits on cellular levels of D-3 phosphorylated
inositol lipids in intact cells, Cos7 cells were transiently
transfected with expression vectors for the different
rCD2–PI 3-kinase chimeras. The cells were metabolically
labelled with [32P]orthophosphate, the phospholipids were
extracted, and the levels of D-3 phosphorylated phospho-
inositides were determined (Fig. 1e). Strikingly, expression
of rCD2p110 caused a four-fold increase in PI(3,4)P2 levels
and approximately a six-fold elevation of PI(3,4,5)P3 levels
compared with basal levels in control cells. The stimulatory
effects of rCD2p110 were due to the catalytic activity of
the membrane-bound p110 protein — expression of equiv-
alent levels of the rCD2p110-R/P mutant did not alter
levels of PI(3,4)P2 and PI(3,4,5)P3. Similarly, expression of
rCD2p85 did not increase cellular levels of PI(3,4)P2 or
PI(3,4,5)P3 (Fig. 1e). We conclude that plasma membrane-
targeting of the p110 catalytic subunit generates a mutant
that is constitutively active in vivo, whereas membrane-tar-
geting of the p85 regulatory subunit has no effect on the
levels of D-3 phosphorylated inositol lipids in vivo.
Immunocomplexes of rCD2p85 contained PI 3-kinase
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activity in vitro as this chimera formed an association with
endogenous PI 3-kinase catalytic subunits (Fig. 1d). The
level of activity in these complexes was extremely low in
comparison to the activity in immunocomplexes containing
rCD2p110, explaining the failure of rCD2p85 to regulate
endogenous levels of D-3 phosphoinositides.
Recent studies have shown that membrane-targeting of
the PI 3-kinase catalytic subunit using a CAAX motif
generates a constitutively active enzyme that activates
the serine/threonine kinases PKB and p70s6k [12], which
play a critical role in the regulation of protein translation
and cell-cycle progression [13]. rCD2p110, but not
rCD2p85 or rCD2p110-R/P, was able to fully replace
serum for activation of PKB and p70s6k (data not shown).
In contrast, rCD2p110 did not activate the mitogen-acti-
vated protein (MAP) kinase ERK1 (data not shown), in
agreement with recent studies showing that PI 3-kinase is
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Figure 1
Construction and characterization of
membrane-targeted rCD2–PI 3-kinase
chimeras. (a) Schematic of the rCD2–PI 3-
kinase chimeras. Numbers correspond to
amino acids in the protein and demarcate the
extracellular, transmembrane, and cytoplasmic
domains. Amino acid 216 depicts the start of
the wild-type p85a or p110a molecules. The
location of the kinase domain (green box) and
the inactivating point mutation R1130P (black
dot) are denoted. rCD2p110 and rCD2p110-
R/P contain a carboxy-terminal myc tag
(triangle). (b) Western-blot analysis of cell
lysates from Cos7 cells transiently transfected
with 10 mg of expression vectors encoding
rCD2p85, rCD2p110, or rCD2p110-R/P,
using anti-rCD2 (Ox34) monoclonal
antibodies. (c) Flow cytometry of Cos7 cells,
from (b), expressing rCD2p85, rCD2p110 and
rCD2p110-R/P stained with anti-rCD2
monoclonal antibodies followed by fluorescein-
conjugated anti-mouse antibody (shaded in
black). As a control, each population of
transfected cells was incubated with mouse
IgG as primary antibody (shaded in grey). (d)
PI kinase activity present in anti-rCD2
immunoprecipitates. Cos7 cells were
transiently transfected with 10 mg of empty
vector (control), or expression vectors
encoding rCD2p85, rCD2p110 or rCD2p110-
R/P, as indicated. Immunoprecipitations and PI
kinase assays were performed as described in
Materials and methods. [32P]phosphate
incorporation into PI (see inset) was quantified
using a PhosphorImager and is expressed as
fmol of [32P]PIP per min. The expression levels
of rCD2–PI 3-kinase chimeras in anti-rCD2
immunoprecipitates were assessed in parallel
by western-blot analysis using anti-rCD2
monoclonal antibodies. Expression levels of
rCD2p110 and rCD2p110-R/P were equal;
rCD2p85 expression levels were about 3-fold
higher than those of rCD2p110 or rCD2p110-
R/P, as quantitated by scanning of protein
band intensities from the autoradiograph and
densitometry analysis. (e) Elevation of
PI(3,4)P2 and PI(3,4,5)P3 levels in intact Cos7
cells by expression of rCD2p110. Cos7 cells
were transfected with 5 mg plasmid DNA
encoding the indicated constructs, labelled
with [32P]orthophosphate, and the levels of
PI(3,4)P2 and PI(3,4,5)P3 were determined.
The data is expressed as fold induction of
basal levels of PI(3,4)P2 and PI(3,4,5)P3 in
control cells. Data were normalized to
PI(4,5)P2 levels in each dish. In control cells,
the values of each polyphosphoinositide were:
PI(4,5)P2, 2 157 362 cpm; PI(3,4)P2, 6 821
cpm; PI(3,4,5)P3, 1 699 cpm. The fold
inductions for rCD2p110 in three independent
experiments were: for PI(3,4)P2: 4.2-, 4.4- and
14.5-fold; and for PI(3,4,5)P3: 5.8-, 8.6- and
3.4-fold. Expression of rCD2–PI 3-kinase
chimeras was checked in parallel by western-
blot analysis using an anti-rCD2 monoclonal
antibody.
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not sufficient to activate the ERKs in mammalian cells
[12]. These data indicate that membrane-localized
rCD2p110 is an effective tool to investigate the cellular
functions of PI 3-kinase.
Expression of active PI 3-kinase leads to membrane
ruffling and stress fibre formation in Swiss 3T3 cells
Cytoskeletal responses triggered by PDGF require PI 3-
kinase activation [16,17]. We used membrane-bound
rCD2p110 to determine whether PI 3-kinase signals were
sufficient to trigger Rac/Rho cytoskeletal signalling path-
ways. Serum-starved subconfluent Swiss 3T3 cells were
microinjected with an expression vector encoding the
active PI 3-kinase rCD2p110, and the pattern of filamen-
tous actin distribution was assessed by immunofluores-
cence in cells expressing rCD2p110 proteins (Fig. 2). Four
hours after injection, polymerized actin was seen to form
localized lamellipodia around the cell margin and, more-
over, to form actin stress fibres (Fig. 2a). These results
were confirmed by time-lapse image recording where sub-
confluent cells expressing rCD2p110 showed active mem-
brane ruffling (data not shown). Swiss 3T3 cells
expressing rCD2p110 also exhibited a polarized cell shape
(Fig. 2a,b). To analyze these cytoskeletal rearrangements
further, quiescent cells were stained for vinculin distribu-
tion, which monitors the formation of Rac-dependent
focal complexes and Rho-dependent focal adhesions [24].
In cells expressing the active PI 3-kinase, vinculin could
be found localized in discrete punctuate spots around the
cell margin forming focal complexes and focal adhesions
in the body of the cell (Fig. 2b). Control cells expressing
the inactive rCD2p110-R/P chimera did not show these
structures (Fig. 2c,d). The changes in cell morphology
triggered by V12Rac and rCD2p110 were qualitatively the
same (compare Fig. 2a,b with 2e,f), although V12Rac
induced the formation of vinculin spots uniformly around
the entire periphery of the cell (Fig. 2f), whereas the
effects of rCD2p110 were localized to discrete areas of the
plasma membrane (Fig. 2b).
Cytoskeletal rearrangements induced by PI 3-kinase are
dependent on endogenous Rac and Rho function
Membrane ruffling and focal complex formation induced
by rCD2p110 were similar to those described for activators
of Rac, whereas the effects of rCD2p110 on actin stress
fibres and focal adhesion assembly were identical to those
described for activators of Rho [19,24]. To assess directly
the role of Rac and Rho in PI 3-kinase-mediated cytoskele-
tal responses, we used N17Rac, a dominant inhibitory
mutant of Rac that prevents activation of endogenous Rac
[19]. To inhibit endogenous Rho function, cells were
microinjected with Clostridium botulinum C3 transferase,
which ADP-ribosylates and inactivates Rho [19]. The
microinjection of N17Rac proteins abolished membrane
ruffles and stress fibre formation in cells expressing active
rCD2p110 (Fig. 2e, compare the right-hand cell with the
left-hand cell). Hence, cytoskeletal rearrangements trig-
gered by active PI 3-kinase are dependent on the function
of Rac proteins. Expression of C. botulinum C3 transferase
inhibited rCD2p110-induced assembly of actin stress
fibres but not the increase in filamentous actin forming
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Figure 2
Distribution of actin and vinculin in Swiss 3T3 cells expressing active
and inactive PI 3-kinase chimeras. Serum-starved sub-confluent
Swiss 3T3 cells were microinjected with plasmids encoding
(a,b,e–g) rCD2p110, (c,d) rCD2p110-R/P, or (h) V12Rac.
rCD2p110-microinjected cells were re-injected after 3 h with
recombinant (e) N17Rac proteins or (f,g) C3 transferase together
with an IgG injection marker. After 3–4 h, or when cells were co-
injected with recombinant proteins 30 min after the second
microinjection, cells were fixed. (a,c,e,f) Actin or (b,d,g,h) vinculin
was visualized by immunofluorescence. In (d) both cells shown were
microinjected; in (e) both cells shown were expressing rCD2p110,
but only the right hand cell was co-injected with N17Rac proteins.
Scale bar = 15 mm.
membrane ruffles (Fig. 2f). Strikingly, in cells where Rho
function was blocked, the active PI 3-kinase induced a
pattern of vinculin staining indistinguishable from that
seen in cells expressing activated V12Rac (compare Fig. 2g
with 2h): focal complexes around the cell margin, but no
vinculin aggregation indicative of Rho-mediated focal
adhesions, could be detected (compare Fig. 2g with 2b).
Collectively, these data show that PI 3-kinase can stimulate
both Rac-dependent pathways for the formation of focal
complexes and membrane ruffling, and Rac/Rho pathways
that induce stress fibre and focal adhesion assembly.
rCD2p110 does not induce SRE-, c-fos-, or Elk-1-
dependent gene expression
An additional function for the GTPases Rac and Rho has
been demonstrated recently: to regulate the transcrip-
tional activity of the c-fos serum response factor (SRF)
[22]. We therefore examined whether PI 3-kinase is a uni-
versal regulator of Rac- and Rho-function by assessing the
ability of rCD2p110 to induce changes in transcriptional
activity of the c-fos SRE. In these experiments, we investi-
gated cellular responses to the expression of constitutively
active mutants of Rac and Rho, and to regulators of
endogenous Rho signalling pathways: serum and Dbl [25],
a guanine nucleotide exchange protein that regulates Rho
family GTPases. SRE activity was monitored with a
SRE–CAT (chloramphenicol acetyl transferase) reporter
gene, which is known to be the target of a signalling
cascade initiated by the GTPases Cdc42, Rac and Rho
[22]. Accordingly, expression of V14Rho or V12Rac stimu-
lated the expression of the SRE–CAT reporter gene to a
level equivalent to the response induced by serum (Fig.
3a). However, no SRE–CAT induction could be observed
in cells expressing the constitutively active PI 3-kinase
alone or in conjunction with suboptimal levels of serum.
Furthermore, expression of rCD2p110 alone did not stim-
ulate c-fos promoter activity (Fig. 3c), nor could it syner-
gize with serum for this response (data not shown). The
expression of Dbl induced SRE activity (Fig. 3b), but
SRE responses triggered by the expression of Dbl or
serum were prevented by co-expression of C3 transferase,
indicating that SRE regulation by these stimuli is medi-
ated by endogenous Rho signalling pathways. Thus, tran-
scriptional activation of the SRE can be regulated by
signalling pathways initiated by serum or by Dbl and
mediated by the GTPase Rho, but these responses cannot
be induced by a constitutively active PI 3-kinase.
Transcriptional activation from the SRE requires SRF
binding. At the c-fos SRE, SRF forms a ternary complex
with TCF (ternary complex factor), which cannot bind the
SRE by itself. One member of the TCF is Elk-1, which is
a substrate for both MAP kinase families, the ERKs
[22,26] and the stress-activated protein (SAP) kinase (also
known as c-jun N-terminal kinase; SAPK or JNK) [27–29].
As Rac has been shown to be involved in regulating the
JNK/SAPK signalling pathway [30,31], we investigated
whether activated rCD2p110 could induce Elk-1 activa-
tion. To monitor Elk-1 transcriptional activity, a fusion
protein comprising the carboxyl terminus of Elk-1 linked
to the LexA repressor [32] was co-transfected into NIH
3T3 cells with a LexA operator-controlled CAT reporter
gene. LexA–Elk-1 transcriptional activity was low in qui-
escent fibroblasts, but could be induced by co-expression
of active Ha-v-ras, by stimulation with serum, or by UV
irradiation (Fig. 3d). However, expression of rCD2p110
did not stimulate Elk-1 activity (Fig. 3d), indicating that a
constitutively active PI 3-kinase cannot stimulate the
UV-activated stress kinase JNK. This observation was
confirmed by direct kinase assays of JNK in vitro (data
not shown).
Expression of the Fos protein is required for the promoter
activity of many genes. Fos is a component of the AP-1
complex, and hence increased cellular levels of Fos pro-
teins can be monitored by assessing whether the activity of
the transcription factor AP-1 becomes upregulated. The
AP-1 complex also contains the transcription factors c-Jun
and ATF2, and is a target for members of both MAP
kinase families, SAPKs and Erks, and their upstream regu-
lators of the Ras and Rho family of GTPases. We deter-
mined the ability of activated Ras and activated PI
3-kinase to induce transcriptional activity of AP-1 com-
plexes: Ha-v-ras led to expression of an AP-1–CAT
reporter gene and synergized with serum for optimal
induction of AP-1–CAT (Fig. 3e); expression of rCD2p110
did not stimulate AP-1 transcriptional activity, nor could it
synergize with Ras or serum-derived signals. The failure of
rCD2p110 to activate SRE, c-fos, Elk-1 or AP-1 transcrip-
tion collectively show that PI 3-kinase signals are not suffi-
cient to stimulate MAP kinase effector pathways activated
by the GTPases of the Ras and Rho family.
Discussion
A chimeric molecule in which the cytoplasmic domain of
the rCD2 cell-surface antigen was replaced with the
p110a subunit of PI 3-kinase allows plasma-membrane
localization of the catalytic subunit of PI 3-kinase. The
membrane-bound rCD2p110 induces accumulation of
cellular levels of PI(3,4)P2 and PI(3,4,5)P3 equivalent to
those seen after mitogenic stimuli: in cells transiently
transfected with rCD2p110, there is an approximate five-
fold increase in cellular levels of PI(3,4,5)P3. As shown in
Figure 1c, 15–20 % of the total population of transiently
transfected Cos7 cells express the rCD2p110 chimeras.
When normalized to the transfection efficiency, this gives
an increase in PI(3,4,5)P3 levels in cells expressing
rCD2p110 of approximately 25–30-fold — well within the
range described for growth-factor induced elevations of
cellular levels of PI(3,4,5)P3. That the rCD2p110 fusion
protein is a useful tool for the investigation of the cellular
responses triggered by PI 3-kinase was confirmed in
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coexpression studies: rCD2p110 activated PKB/Akt and
p70s6k but not the ERKs (data not shown).
Here, we show that PI 3-kinase signals are sufficient to
induce cytoskeletal changes that include actin polymeriza-
tion, resulting in Rac-mediated formation of membrane
lamellipodia and focal adhesions and Rho-induced forma-
tion of actin stress fibres and focal complexes. Moreover,
we show that endogenous Rho and Rac functions are
required for these processes, respectively. It is now recog-
nized that Rho family GTPases play an important role in
the activation of transcription factors and hence are con-
tributing to the regulation of cell growth. The ability of PI
3-kinase signals to initiate the Rac/Rho-mediated
responses in the context of the actin cytoskeleton raises
the issue of whether PI 3-kinase is a universal activator of
Rac/Rho signal transduction pathways. The present data
show that expression of constitutively active PI 3-kinase
cannot induce Ras/Rac/Rho signalling pathways that regu-
late gene transcription from SRE, c-fos, Elk-1 or AP-1
reporters. PI 3-kinase signals also could not synergize with
serum to induce gene expression from these CAT
reporters. In contrast, activation of endogenous GTPases
with serum or by expression of Dbl could activate Rho-
mediated stress fibre formation [33] and Rho-mediated
SRE transcriptional activation (Fig. 3b). Similarly, studies
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Figure 3
rCD2p110 does not induce SRE- or c-fos-
dependent gene expression. NIH 3T3 cells
were transfected with (a,b) the SRE–CAT
reporter, (c) the c-fos–CAT reporter, (d) the
LexA operator-controlled CAT reporter
(LexA–CAT) plasmid plus the expression
plasmid producing the LexA–Elk-1 fusion
protein (Nlexelk-1), or (e) the AP-1 CAT
reporter plasmid, together with the expression
plasmids encoding rCD2p110, rCD2p110-
R/P, V14Rho, V12Rac, Dbl, or Ha-v-ras
(H-ras), as described in Materials and
methods. In (c), 3 mg V14Rho was used.
Serum-starved NIH 3T3 cells were treated as
indicated with 40 J m–2 UV-C or 20 % FCS
when not shown otherwise (a–d), or with 4 %
FCS (e). The data are from a representative
experiment. Similar results were obtained in
four (a,e), two (b,d) or three (c) further
experiments. The data are presented as the
ratio of CAT activity (percentage conversion)
to b-galactosidase optical density (OD) units.
250
200
150
100
50
0
SRE–CAT
+
 4
 %
 F
C
S
C
AT
 a
ct
iv
ity
+
 4
 %
 F
C
S
(a)
Co
ntr
ol
Co
ntr
ol
FC
S
V1
4R
ho
V1
2R
ac
rC
Dp
11
0
rC
D2
p1
10
rC
D2
p1
10
-R
/P
40
30
20
10
0
LexA–CAT + Nlexelk-1
C
AT
 a
ct
iv
ity
(d)
Co
ntr
ol UV FC
S
Ha
-ra
s
rC
D2
p1
10
rC
D2
p1
10
-R
/P
250
150
50
0
SRE–CAT
C
AT
 a
ct
iv
ity
(b)
20
15
10
5
0
c-fos–CAT
C
AT
 a
ct
iv
ity
(c)
Co
ntr
ol
FC
S
V1
4R
ho
V1
2R
ac
rC
D2
p1
10
rC
D2
p1
10
-R
/P
150
100
50
0
AP-1–CAT
C
AT
 a
ct
iv
ity
(e)

–C3
+C3
Control FCS V14Rho Dbl  FCS H-ras FCS
Co
ntr
ol
rC
D2
p1
10
rC
D2
p1
10
H-
ras
– – –  FCS– 

have shown that Dbl can induce Rac-mediated actin
cytoskeleton responses and Rac-mediated JNK/SAPK
activation [30,31]. Our results demonstrate that PI 3-
kinase induces a selective subset of cellular responses but
is not sufficient to stimulate the full range of Rac- or Rho-
coordinated pathways. PI 3-kinase is therefore not a uni-
versal activator of Rac/Rho-mediated signalling cascades.
To explain this phenomenon, it is necessary to evoke dis-
crete subpopulations of these GTPases that are linked to
different upstream regulatory proteins and diverse effector
pathways. The existence of diverse effector molecules for
Rac and Rho has been established, mainly by studies of
proteins that interact with Rac and Rho: the p21-associ-
ated kinase (Pak1) binds to and is activated by GTP-
bound Rac or Cdc42 [34]. A different novel target of Rac,
POR1, may link Rac to cellular responses controlling
membrane ruffling [35]. Similarly, two different protein
kinases, PKN [36,37] and p164 Rho kinase (ROK) [38,39]
associate with active Rho. ROK may act as the Rho effec-
tor controlling stress fibre formation by inhibiting myosin
light-chain phosphatase [40,41], but its role in coupling
Rho to the regulation of transcription factors is unclear.
The present study suggests that different Rac and Rho
effectors are not necessarily coordinately activated and may
be triggered by distinct intracellular signalling pathways.
Hence, PI 3-kinase signals can induce Rac/Rho-mediated
cytoskeletal changes without activating Rac/Rho-mediated
transcription factor pathways. Expression of Dbl activates a
wider repertoire of Rac/Rho cellular responses than the
membrane-targeted PI 3-kinase. These observations could
be explained by several models, described below, which
imply spatial restrictions of Rac/effector complexes.
In a simplistic model, the failure of PI 3-kinase-activated
Rac to interact with the full range of Rac effector mole-
cules could result from subcellular compartmentalization
of different pools of these proteins. For example, pool 1 of
Rac/Rho effectors involved in cytoskeletal rearrangements
could be constitutively membrane-localized: receptor acti-
vation of PI 3-kinase will generate D-3 phosphoinositides
in the plasma membrane, which would spatially restrict
the regulatory capacity of these lipids to only membrane-
localized pools of Rac/Rho effectors. The expression of
oncogenic Dbl is not confined to the plasma membrane
and Dbl would come into contact with both pools of
Rac/effector complexes, including pool 2, which has a
more cytoplasmic distribution and transduces transcrip-
tional activation. The discrepancy between the functional
effects of Dbl and active PI 3-kinase could then be
explained by their different cellular localization. Evidence
from a recent study supports this type of model: the pleck-
strin homology (PH) domain of Dbl targets the protein to
specific cytoskeletal locations, and a plasma membrane-
targeted Dbl with a truncated PH domain is not fully
active [42].
A second spatial model, in which pool 2 of effector pro-
teins are actively recruited, allows for the potential of
additional signals derived from growth factors (spatial
model 2; Fig. 4a). Such signals would recruit different
pools of Rac effector molecules into the proximity of Rac
activated by PI 3-kinase. Hence, PI 3-kinase signals may
be able to cooperate with other signals generated from
growth factors to allow full induction of Rac/Rho-medi-
ated signalling pathways, in particular the activation of
transcription factor responses. In this context, a recent
report describes that the adaptor protein Nck binds to the
Rac effector kinase Pak1 [43]; this result is consistent with
a mechanism that recruits Pak1 into activated growth-
factor receptor complexes and hence to sites in the mem-
brane containing Rac activated by PI 3-kinase. Whether
this is the case remains to be elucidated, yet PI 3-kinase
signals did not concur with serum-derived signals to give
activation of gene expression. Therefore, an alternative
model to activate Rac/Rho-mediated gene transcription
may involve an independent, as yet uncharacterized,
mechanism that does not involve PI 3-kinase —
autonomous regulation of pool 2 of effector proteins
(spatial model 3; Fig. 4b).
The identity of the direct targets for D-3 phosphoinosi-
tides that regulate the activation of Rac and Rho is cur-
rently unknown. The activity of Rho family GTPases is
controlled by the concerted action of guanine nucleotide
exchange factors (GEFs), guanine nucleotide dissociation
inhibitors (GDIs) and GTPase activating proteins (GAPs).
Which of these will be targeted by D3 phosphoinositides
is not clear but it is tempting to speculate that PH
domains, which have been shown to bind phosphoinositol-
lipids and are present in Rho family GEFs, could provide
the link between lipid kinases and Rac/Rho. However,
any model for regulation of Rho family GTPases must
include a mechanism to explain how growth factors appar-
ently have the ability to activate Rac and Rho by mecha-
nisms autonomous of PI 3-kinase. For example, the
lysophosphatidic acid (LPA) receptor can bypass PI 3-
kinase and Rac to stimulate Rho-dependent responses by
a different route. Finally, as demonstrated by the present
report, models for activation of Rac and Rho must be
superimposed by models that allow for selective activation
of different Rac/Rho effectors by diverse regulatory pro-
teins with the subsequent stimulation of divergent cellular
responses.
Conclusions
Rho family GTPases have been shown to be important for
the regulation of different cellular responses, including
gene transcription, the activation of certain members of the
MAP kinase family, and changes in the actin cytoskeleton.
Although it is becoming evident that these diverse cellular
responses are mediated by different effector proteins that
associate with the activated GTPase complexes, little is
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known of how growth factor receptors orchestrate these
distinct effector pathways, in particular whether triggering
of the receptor will uniformly activate all cellular pathways
mediated by a certain GTPase.
PI 3-kinase is activated by many growth factor receptors,
leading to an increase in D-3 phosphoinositides in the
plasma membrane. PI 3-kinase-derived signals are suffi-
cient to induce growth factor-like changes of the actin
cytoskeleton mediated by the GTPases Rac and Rho, but
are not sufficient to stimulate Rac/Rho-mediated gene
transcription. Hence, PI 3-kinase activates a distinct
subset of Rac/Rho effector pathways but does not give the
full repertoire of GTPase responses. Our data suggest,
therefore, that it is possible to selectively activate differ-
ent GTPase effector pathways. We propose that specific
subcellular compartmentalization mechanisms exist that
localize different exchange factor/GTPase complexes to
divergent downstream effector pathways.
Materials and methods
Construction of chimeric cDNAs
The coding regions of bovine p85a [44] and p110a [2] were attached
to a truncated rat CD2 molecule consisting of the extracellular and
transmembrane domain (EMBL accession number X05111; [45]). The
rCD2 intracellular domain was truncated at the stop transfer sequence
(amino acids 1–212) by the addition of a NotI site. The p85a and
p110a subunits were adapted with a NotI site at the 5′ end omitting
the methionine of the leader sequence and introducing the peptide
SGR in the coding sequence at the hinge. The NotI-p110 construct
was tagged at the carboxyl terminus with the Myc epitope [46]. To con-
struct the inactive rCD2p110-R/P, a 533 bp PstI–NcoI cartridge from
NotI-p110 was replaced with the corresponding cartridge from the
described p110-BamHI plasmid containing the R916P mutation [23].
The rCD2-PI 3-kinase chimeras were assembled by subcloning the
mutated cDNAs into the pcDNA3 vector (Invitrogen) (Fig. 1) or a
human cytomegalovirus (CMV) promoter-driven expression vector [47]
(Figs 2,3). All obtained constructs were verified by nucleotide sequenc-
ing and/or restriction enzyme analysis.
Plasmids and reporter constructs
Ha-v-ras [48], V14Rho, V12Rac and C3 transferase [22] vector con-
structs have been described. For the microinjection experiments,
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Figure 4
Models for the contribution of PI 3-kinase
signals to the activation of Rac and Rho
GTPase effector pathways. (a) Spatial model 2:
recruitment of pool 2 of effector proteins. PI 3-
kinase signals activate Rac via the stimulation
of guanine nucleotide exchange factors (GEF)
or possibly via inhibition of GTPase activating
proteins (GAPs). The activated GTP-bound Rac
is subsequently able to interact with the pool of
effector molecules that link Rac activation to
the actin cytoskeleton. Further induction of
Rac/Rho-mediated pathways for activation of
gene transcription requires a second growth
factor-derived signal that will recruit the Rac
effector molecules involved in MAP kinase
activation into the proximity of PI 3-kinase
activated Rac. Y indicates a phosphotyrosine
residue and PH indicates a pleckstrin homology
domain. (b) Spatial model 3: autonomous
regulation of pool 2 of effector proteins. PI 3-
kinase activation triggers membrane ruffles and
stress fibre formation that entangles pool 1 of
Rac/effector complexes situated in the
proximity of the plasma membrane. To trigger
GDP/GTP exchange on Rac GTPases that
couple to pool 2 of effector proteins, an
independent mechanism is evoked by the
activated growth-factor receptor. This may
involve an uncharacterized upstream signalling
molecule (X) that activates Rac at a different
subcellular location where Rac proteins are
networked to pool 2 of effector proteins. Note:
in these models, only guanine nucleotide
exchange factors (GEFs) or GTPase activating
proteins (GAPs) are depicted as regulators of
Rho family GTPase activity. Equally possible is
the regulation of Rho family GTPases via
guanine nucleotide dissociation inhibitors
(GDIs). Which regulatory mechanism is
engaged is currently not clear, and may involve
a combination of all three sets of Rho family
regulators.
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V12Rac was expressed as myc-tagged derivative from the CMV pro-
moter-driven vector (see above). Human Dbl (amino acids 495–826;
EMBL accession number X12556) was expressed as myc-tagged
derivative from the CMV promoter-driven vector (see above) and kindly
provided by M.F. Olson. The reporter plasmids have been described:
pMLVNlex.elk-1, 2lexoptk.CAT [32]; AP-1.CAT [49]; wild-type
SRE.CAT [50]; c-fos CAT [51].
Cell culture, transient transfections and metabolic labelling
Cos7 cells, Swiss 3T3 cells and NIH 3T3 cells were maintained in Dul-
becco’s modified Eagle’s medium (DMEM) supplemented with 10 %
fetal calf serum (FCS).
Cos7 cells were transfected by electroporation (450 V, 250 mF) with
5–10 mg of plasmid DNA. After 47 h cells, were collected. When cells
were metabolically labelled, cells were washed extensively after 36 h,
labelled with [32P]orthophosphate (1 mCi per dish) in Pi-free DMEM
containing 0.8 % dialyzed FCS and 20 mM Hepes for 8 h and phos-
pholipids were extracted. NIH 3T3 cells were transfected by the diethy-
laminoethyl (DEAE)-Dextran method [50]. DNA concentrations in each
experiment were constant (generally 8 mg) by adding vector plasmid.
Transfected cells were serum-deprived for 36 h, stimulated by UV irra-
diation or addition of FCS as indicated and harvested after 8–10 h.
Western-blot analysis
Transfected Cos7 cells were washed with PBSA and lysed in 0.5 ml
Cos7 lysis buffer (1 % (w/v) Triton X-100, 20 mM Tris pH 7.5, 137 mM
NaCl, 15 % (v/v) glycerol, 2 mM EDTA, 2 mM PMSF, 20 mg ml–1 apro-
tinin, 2 mM benzamidine, 1 mM sodium orthovanadate, and 2 mg ml–1
of the small peptide inhibitors leupeptin, pepstatin A and chymostatin).
Western-blot analysis of total postnuclear cell lysates or immunopre-
cipitates was performed as described [52] using Ox34 monoclonal
antibody raised against rCD2 [45].
Immunoprecipitation of rCD2-PI 3-kinase chimeras and PI
kinase assays
Transfected Cos7 cells were washed with PBSA and lysed in 0.5 ml
Cos7 lysis buffer (see above). Postnuclear lysates were precleared
with protein A cell suspension (Sigma) prior to precipitation with anti-
rCD2 monoclonal antibody and rabbit anti-mouse IgG (DAKO) precou-
pled to protein A-Sepharose beads (Sigma). When PI kinase assays
were performed the immunoprecipitates were washed once in Cos7
lysis buffer, twice in washing buffer 1 (100 mM Tris pH 7.5, 0.5 M LiCl
and 100 mM sodium orthovanadate) and twice in washing buffer 2
(50 mM Hepes pH 7.4, 100 mM NaCl, 1 mM EDTA and 100 mM
sodium orthovanadate). The washed immunoprecipitates were resus-
pended in 10 ml lipid mixture (1 mg ml—1 each L-a-phosphatidylinositol
and L-a-phosphatidyl-L-serine, dispersed by sonication in 25 mM
Hepes pH 7.4 and 1 mM EDTA). The reaction was initiated by the addi-
tion of 40 ml PI-kinase reaction buffer (containing 100 nM [g-32P]ATP
(10 mCi), 125 mM ATP, 12.5 mM MgCl2, 125 mM NaCl, 25 mM Hepes
pH 7.4 and 250 mM adenosine). After 15 min at 25 °C, the reaction
was terminated and the samples processed as described [52]. Incor-
poration of 32P into PI was quantified using a PhosphorImager (Molecu-
lar Dynamics). The [32P]PIP counts obtained for each sample were
normalized to the specific activity of the [g-32P]ATP used for the assay,
and are expressed as fmol of PIP per min.
HPLC analysis of inositol phosphates
Phospholipid extractions were based on the method described previ-
ously [53]. Briefly, cells were washed with PBSA, collected in 1 ml
2.4 M HCl and transferred to a polypropylene test tube. CHCl3:MeOH
(1:2 v/v) (1.5 ml) containing 10 mg phosphoinositides (Sigma) to act as
carrier lipids were added followed by 1 ml CHCl3. After vortexing and
centrifugation the lower phase was removed to a fresh tube, the upper
phase was re-extracted twice with 1.5 ml of CHCl3 and the CHCl3
phases were combined. Dry lipid films were deacylated with 0.5 ml
methylamine at 50 °C for 1 h in the presence of 50 ml n-butanol. The
resulting glycerophosphoinositol esters were re-dissolved in 0.5 ml water
and extracted once with an equal volume of n-butanol. The aqueous
phase was mixed with 3H-labelled IP4 (Du Pont) as an internal standard
[54] and resolved by anion-exchange on HPLC using a S5 SAX column
(Phase Separations). The column was eluted at 1 ml min–1 with a linear
gradient of Milli Q water versus 2.5 M NaH2PO4 (pH 3.8 with NaOH
(% B)); times were t = 0, % B = 0; t = 10, % B = 0; t = 60, % B = 12; t =
70, % B = 19; t = 110, % B = 50, t = 130, % B = 50; t = 140, % B = 0;
fractions were collected every 0.5 min. The data are collected as values
of 32P and 3H radioactivity measured using a calibrated 3H/32P dual-label
program on a Beckman LS6000 series scintillation counter.
Microinjection experiments
Serum-starved sub-confluent Swiss 3T3 cells were prepared for
microinjection as described [55]. Plasmid DNAs were microinjected at
200 mg ml–1 in PBS into the nucleus. After 3–4 h, cells were fixed with
4 % paraformaldehyde (w/v). To prevent activation of endogenous Rac
and Rho proteins, rCD2p110 microinjected cells were re-injected with
recombinant N17Rac proteins (0.7 mg ml–1) and C3 transferase
(100 mg ml–1), respectively, and after 30 min cells were fixed. Vinculin
or actin was visualized by immunofluorescence, essentially as
described [55]. Briefly, permeabilized cells were double-labelled for
actin and protein expression by first incubating with Ox34 monoclonal
antibody to detect rCD2–PI 3-kinase chimeras. Then cells were incu-
bated with FITC-conjugated goat anti-mouse antibody, and for detec-
tion of actin, with rhodamine–phalloidin (0.1 mg ml–1). For re-injection
experiments, recombinant proteins were co-injected together with rat
IgG (0.5 mg ml–1) as an injection marker which was visualized using a
cascade blue-conjugated goat anti-rat IgG. For vinculin-staining cells
were co-injected with Texas Red-lysinated dextran (2 mg ml–1) as an
injection marker. Vinculin was localized as described [55]. Recombinant
N17Rac proteins and C3 transferase were prepared as described [19].
Gene expression analysis
8–10 h after inductions as indicated, transfected serum-starved NIH 3T3
cells were washed with PBSA and cells were lysed in 150ml lysis buffer
(0.65 % Triton-X100, 10 mM Tris pH 8, 1 mM EDTA and 150 mM NaCl).
Gene expression assays were carried out essentially as described [56].
The following amounts of plasmid were used: rCD2p110 (0.5mg),
rCD2p110-R/P (0.5 mg), V14Rho (1 mg), V12Rac (1 mg), Dbl (1 mg) or
C3 transferase (2 mg). 4 mg of CAT reporter constructs and 0.25mg of
pMLVNlex.elk-1 were used. Transfection efficiency was monitored with
appropriate b-galactosidase (lacZ) expression vectors (used at 1 mg) as
described [57]. The data are presented as the ratio of CAT activity (per-
centage conversion) to b-galactosidase optical density (OD) units.
Other methods
Cos7 cells were subjected to immunofluorescent staining and flow
cytometry using the Ox34 monoclonal antibody and for control staining
mouse IgG (Sigma) followed by FITC-conjugated rabbit anti-mouse
IgG (DAKO) employing standard protocols.
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Note added in proof
Didichenko, Thelen and colleagues (Curr Biol 1996, 6:1271–1278) have
recently described the effect of expressing a membrane-targeted PI 3-
kinase on protein kinase B (PKB) and p47phox. Their data confirm that
membrane-targeting of the p110a catalytic subunit of PI 3-kinase leads to
elevation of PI(3,4,5)P3 levels in cells and that expression of membrane-
localized  PI 3-kinase results in the continuous activation of PKB.
Interestingly, the authors show that PI 3-kinase signals lead to constitutive
phosphorylation of p47phox, a cytosolic factor required for the assembly of
the phagocyte NADPH oxidase. As Rac is an essential component of the
NADPH oxidase complex, it will be interesting to analyze whether Rac is
involved in events leading to the phosphorylation of p47phox.
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